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Abstract
Introduction Preterm birth (PTB) may be preceded by
changes in the vaginal microflora and metabolite profiles.
Objectives We sought to characterise the metabolite
profile of cervicovaginal fluid (CVF) of pregnant women
by 1H NMR spectroscopy, and assess their predictive value
for PTB.
Methods A pair of high-vaginal swabs was obtained from
pregnant women with no evidence of clinical infection and
grouped as follows: asymptomatic low risk (ALR) women
with no previous history of PTB, assessed at 20–22 ges-
tational weeks, g.w., n = 83; asymptomatic high risk
(AHR) women with a previous history of PTB, assessed at
both 20–22 g.w., n = 71, and 26–28 g.w., n = 58; and
women presenting with symptoms of preterm labor (PTL)
(SYM), assessed at 24–36 g.w., n = 65. Vaginal secretions
were dissolved in phosphate buffered saline and scanned
with a 9.4 T NMR spectrometer.
Results Six metabolites (lactate, alanine, acetate, glu-
tamine/glutamate, succinate and glucose) were analysed. In
all study cohorts vaginal pH correlated with lactate integral
(r = -0.62, p\ 0.0001). Lactate integrals were higher in
the term ALR compared to the AHR (20–22 g.w.) women
(p = 0.003). Acetate integrals were higher in the preterm
versus term women for the AHR (20–22 g.w.) (p = 0.048)
and SYM (p = 0.003) groups; and was predictive of
PTB\ 37 g.w. (AUC 0.78; 95 % CI 0.61–0.95), and
delivery within 2 weeks of the index assessment (AUC
0.84; 95 % CI 0.64–1) in the SYM women, whilst other
metabolites were not.
Conclusion High CVF acetate integral of women with
symptoms of PTL appears predictive of preterm delivery,
as well as delivery within 2 weeks of presentation.
Keywords Cervicovaginal fluid  Metabolites 
Pregnancy  Preterm birth  Nuclear magnetic resonance
(NMR)
1 Introduction
Preterm birth (PTB), defined as birth before 37 weeks of
gestation, is the most notable cause of perinatal morbidity
and mortality worldwide (Blencowe et al. 2013; Hamilton
et al. 2013). Approximately 15 million PTBs (about 11.1 %
of all births) occur annually (Blencowe et al. 2013), costing
in excess of $26 billion to health care providers annually
(MacDorman et al. 2007).
Approximately two-thirds of PTBs occur without an
identifiable cause and follow spontaneous onset of preterm
labor (PTL), whilst a third of cases are associated with
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preterm premature rupture of membranes (Goldenberg
et al. 2008). About 25–40 % of PTBs are associated with
intrauterine infection or inflammation (Goldenberg et al.
2008; Romero et al. 2001). Changes in the vaginal
microflora have been implicated in the pathogenesis of
ascending intrauterine infection (Racicot et al. 2013;
Romero et al. 2006), and may be undetectable using con-
ventional culture-dependent techniques (DiGiulio et al.
2008).
An approach to elucidating the host-microbial changes
associated with PTB is to identify the metabolite changes
associated with these interactions. Vaginal bacterial colo-
nization and infection results in the release of lipopolysac-
charides, peptidoglycans and short chain fatty acid, which
evoke deciduitis and chorioamnionitis. Subsequently proin-
flammatory chemokines and cytokines such as TNF-a,
IL1-a, IL-1b, IL-6, IL-8, and granulocyte colony stimulating
factor, are synthesized and released (Goldenberg et al.
2000a; Kawai and Akira 2011; Mirmonsef et al. 2012;
Schenten and Medzhitov 2011). These trigger a cascade of
responses including the release of matrix metalloproteinases
(e.g. MMP-8) (Rahkonen et al. 2009a; Witkin et al. 2013),
and prostaglandins (e.g. PGE2 and PGF2a), (Goldenberg
et al. 2000b; Romero et al. 2006), some of which degrade the
extracellular matrix proteins of the cervix and chorioamni-
otic membrane causing cervical remodeling, rupture of the
fetal membranes and myometrial contractions, leading to
PTB (Goldenberg et al. 2000b; Romero et al. 2006; Witkin
et al. 2013).
Measures to predict the risk of PTB are few, being
confined to evaluation of a previous history of PTB, a short
cervix (\25 mm) on second trimester ultrasonography
(Crane and Hutchens 2008; Goldenberg et al. 2008; Mella
and Berghella 2009), and the assessment of cervicovaginal
fluid (CVF) for fetal fibronectin (Honest et al. 2009), and
phosphorylated insulin-like growth factor binding protein-1
(phIGFBP-1) (Rahkonen et al. 2009b), amongst other
analytes. Each of these tests has its limitations, the prin-
cipal one being low positive predictive values (Di Renzo
et al. 2011). The detection of clinical infection has not been
shown to be predictive of PTB and data regarding the
pathogenic role of bacterial vaginosis (BV) is unclear
(Donders et al. 2010; Guaschino et al. 2006). A need
subsists to identify new biomarkers that reliably predict
PTB (Honest et al. 2006).
The assessment of metabolite markers of tissue and
microbial anaerobic and aerobic glycolysis is finding
increasing application in characterizing physiological and
disease states (Auray-Blais et al. 2011; Ghartey et al. 2015;
Horgan et al. 2009; Mamas et al. 2011). A recent study has
identified differences in the metabolite profiles of women
with BV compared to women without the infection
(Srinivasan et al. 2015).
It is plausible that the cervicovaginal ecosystem of com-
mensal and pathogenic organisms may generate metabolite
markers that may predict the risk of PTL and PTB. A tech-
nique for assessing such metabolite changes is nuclear
magnetic resonance (NMR) spectroscopy. Recently, NMR
has been employed to show that vaginal secretions rich in
species of Lactobacillus were associated with high amounts
of lactate (Bai et al. 2012; Gajer et al. 2012). Additionally,
acetate, butyrate, succinate and propionate levels were high
in vaginal samples dominated by anaerobic bacteria such as
Atopobium, Megasphera, Parvimonas, Mobiluncus, Pre-
votella etc. (Bai et al. 2012).
We therefore sought to characterize the metabolite
profile of CVF obtained from cohorts of pregnant women
who deliver prematurely compared to those who do not,
categorizing the participants by whether they were at high-
risk of PTB or not, and by presentation with symptoms of
PTL. We hypothesized that the 1H NMR spectrum of CVF
may reliably predict pregnant women who deliver prema-
turely, as well as women with symptoms of PTL who
deliver shortly after assessment.
2 Materials and methods
These studies were approved by the Yorkshire & Humber
(Sheffield) Committee of the UK National Research Ethics
Service (REC Number 13/YH/0167).
The study participants comprised of two clinical cate-
gories of pregnant women: those that had no symptoms of
PTL (asymptomatic group) and those presenting to the
delivery suite with symptoms of, but not established, PTL.
The asymptomatic pregnant women were further classified
into 2 gestationally-matched groups based on a previous
history of PTB: a low-risk group (ALR), who had no
previous history of PTB (assessed at 20–22 gestational
weeks, g.w., n = 83), and a high-risk group (AHR), who
had a previous history of PTB (n = 71, assessed at 20–22,
and repeated at 26–28 g.w., n = 58). The third study group
(SYM) comprised women presenting with clinical symp-
toms of PTL but who were not in established labor (in-
frequent uterine contractions less than thrice every 10 min,
cervix \4 cm dilated, and intact fetal membranes,
24–36 g.w., n = 65). The SYM group was studied before
any clinical therapy was initiated and women who were
already on tocolytic or antibiotic drugs or any form of
vaginal topical therapy were excluded from study. All
participants were recruited via the antenatal clinics and
Triage Delivery Suites of the Jessop Wing Hospital,
Sheffield, UK.
At presentation, a pair of high vaginal samples was
obtained with dry polystyrene Dacron swabs (Deltalab
Eurotubo 300263, Fisher Scientific, UK) from each woman
67 Page 2 of 11 E. Amabebe et al.
123
following written informed consent. The collected samples
were immediately processed or stored in a refrigerator at
-20 C, for up to 3 days, pending analysis. The clinical
course and delivery outcomes of participants were subse-
quently ascertained. Women with multiple gestation, bac-
teriologically proven infection, and history of abnormal
cervical cytology within 3 years, ruptured fetal mem-
branes, and prior vaginal examination at presentation were
excluded from the study.
2.1 1H NMR sample preparation
The end of the swab soaked with the vaginal fluid sample
was cut off and placed in a 1.5 ml microfuge tube. Six
hundred microlitre of Phosphate Buffered Saline at pH 7.4
was added to the tube as an extraction solvent. The vaginal
fluid was washed off the swab by vortexing for 5 min, after
which the swab was removed and safely discarded. The
solution was then centrifuged at 13,000 rpm for 3 min to
separate swab particles from the vaginal fluid solution. The
supernatant was carefully aspirated into a separate clean
1.5 ml microfuge tube and stored at -80 C ready for
analysis. Prior to 1H NMR analysis, a total of 400 ll of
each sample comprising of 380 ll of vaginal fluid in
solution and 20 ll of deuterium oxide (D2O) was trans-
ferred into a 5 mm NMR tube. An unused (sterile) poly-
styrene Dacron swab was also prepared as above and
analyzed using the same protocol as a background signal
control. This was repeated at regular intervals or change of
swab batch to control for swab manufacturing variations.
2.2 1H NMR spectroscopy
Using a 9.4T Bruker Avance III NMR spectrometer (Bru-
ker BioSpin GmbH, Karlsruhe, Germany), with 5 mm
broadband observe probe, 1H NMR spectra were acquired
using the Watergate water suppression pulse sequence
(NS = 256, D1 = 5 s, AQ = 1 s, SW = 20.6 ppm,
TD = 16,446), for each of the vaginal samples. All 1H
NMR experiments were performed at approximately
21 C. Data was acquired and processed using the Bruker
Topspin 2.1.6 software to produce a phase and baseline
corrected spectrum. All spectra were referenced to the 1H
lactate signal at d = 1.33 ppm. Identified metabolite sig-
nals in the 1H NMR spectra were integrated for peak area
(which is proportional to metabolite concentration). To
correct for differences in vaginal fluid concentration (vari-
ation in the swab sampling), each metabolite integral was
divided by the total spectrum integral (d = 0.0–10.0 ppm,
excluding the residual water signal between d = 4.7–5.0
ppm) to provide a normalized integral (N.I.) (Bai et al.
2012; Gajer et al. 2012).
2.3 Assigning the NMR spectral peaks
In order to assign metabolites to the 1H NMR spectra, 2-D
1H-1H and 1H-13CNMRspectrawere obtained.The following
2-DNMRspectrawere acquired in order to assignmetabolites
to the 1H NMR spectral peaks: 1H-13C presat-HSQC
(Heteronuclear Single Quantum Correlation spectroscopy)—
NS = 1024, D1 = 1 s, AQ = 0.078 9 0.006 s, SW =
10.0 9 150 ppm, TD = 624 9 180; 1H-13C presat-HMBC
(Heteronuclear Multiple Bond Correlation spectroscopy)—
NS = 1024, D1 = 1 s, AQ = 0.128 9 0.005 s, SW =
10.0 9 200 ppm, TD = 1024 9 200; 1H-1H watergate-
DQFCOSY (Double Quantum Filtered Correlation spec-
troscopy)—NS = 256,D1 = 0.5 s, AQ = 0.832 9 0.022 s,
SW = 9.0 9 9.0 ppm, TD = 6000 9 160; and 1H-1H pre-
sat-cleanTOCSY (Total Correlation spectroscopy)—NS =
16, D1 = 1.5 s, AQ = 0.284 9 0.071 s, SW = 9.0 9 9.0
ppm, TD = 2048 9 512.
2.4 Vaginal fluid pH and fetal fibronectin
measurement
During vaginal fluid sample collection, the vaginal pH was
also determined by obtaining a sample of vaginal discharge
from the lateral vaginal wall with the aid of a dry swab and
smeared on a narrow range pH paper (pH-Fix, Macherey–
Nagel, DE, range 3.6–6.1).
Fetal fibronectin level was quantified using a bedside
immunoassay—quantitative Rapid fFN 10Q analyzer
(Hologic, Marlborough, MA).
2.5 Polymerase chain reaction
Vaginal microbial DNA was extracted and amplified with
QIAamp DNA mini kit (Qiagen, UK) and genus-specific
primers targeted at the bacterial 16S rRNA gene (Supple-
mentary Table S1), to examine for a range of commensal and
potential pathogenic species (details in SupplementaryFile 1).
2.6 Statistical analysis
All Statistical and ROC curve analysis were performed
using MATLAB (Mathworks, Natick, MA), Both Wil-
coxon rank-sum test and ANOVA, with Bonferroni Post-
Hoc test were performed to compare differences in
metabolite N.I. between and within the groups. Values are
quoted as mean ± SE unless otherwise stated. The pre-
dictive potential of the vaginal fluid metabolites for PTB
was determined by receiver operating characteristics
(ROC) curves for the following comparisons:
• Preterm (\37 weeks) versus term births in all groups
• \32 versus[32 g.w. in symptomatic women
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• \2 versus[2 weeks from presentation to delivery in
symptomatic women
Predictive accuracy was also determined for metabolite
N.I. as sensitivity, specificity, negative and positive pre-
dictive values, as well as likelihood ratios (Akobeng 2007;
Altman and Bland 1994).
3 Results
3.1 Pregnancy outcomes
Table 1 summarizes the clinical details of the participant
cohorts. Only 1.2 % of the ALR women delivered preterm
(single birth). Prevalence of PTB in the AHR women was
36.6 and 29.3 % in the 20–22 and 26–28 g.w. groups
respectively. Of women presenting with symptoms of PTL
(SYM), 83.1 % went on to deliver at term, while 16.9 %
delivered preterm. The mean time between presentation
and delivery was 14.5 ± 4.4 and 61.6 ± 3.7 days for
preterm and term-delivered SYM women respectively.
3.2 Treatment interventions
A subset of the AHR group had undergone clinical therapy by
the time of their assessment at 20–22 g.w. (cervical cerclage
12 %; progesterone 8 %; betamethasone 2 % and antibiotics,
40 %), and at 26–28 g.w. (cervical cerclage 13 %; proges-
terone 23 %; betamethasone 11 %; and antibiotics 70 %).
3.3 Cervical length and fetal fibronectin
concentration
The term-delivered ALR had significantly longer cervical
lengths (Table 1), compared to the term (p = 0.01) and
preterm-delivered (p\ 0.00001) women in the AHR (20-
22 g.w.) group. Similar term vs preterm differences were
observed within the AHR (20-22 g.w.) (p = 0.002), and
AHR (26–28 g.w.) groups (p = 0.004).
The ALR women that delivered at term had significantly
lower fetal fibronectin levels (Table 1), compared to the
preterm AHR (20–22 g.w.) women (p\ 0.001). A similar
result in relation to delivery outcome was observed within
the AHR (26–28 g.w.) group (p\ 0.001).
No differences in cervical length and fetal fibronectin
level were observed in the SYM group.
3.4 NMR integration
Six metabolite signals of interest were identified in the 1H
NMR spectra (Fig. 1). These were lactate, alanine, acetate,
glutamine/glutamate, succinate, and glucose. These metabo-
lites were analysed due to their association with the vaginal
microbiota and impact on vaginal pH (Srinivasan et al. 2015,
Aldunate et al. 2015). The glucose signal at d = 5.2 ppm
was integrated and used in subsequent analysis to avoid
influence from other peaks in the glucose signal region of
3.2–3.9 ppm. Comparison of mean 1H metabolite N.I. from
the different cohorts in relation to delivery outcomes is
shown in Fig. 2 and Supplementary Fig. S1. There were no
differences in the 1HNMR total spectrum absolute integrals,
indicating that vaginal fluid concentration did not vary
significantly between the groups (Supplementary Fig. S2).
3.5 Lactate
The lactate N.I. of the term ALR women was significantly
higher than that of the term and preterm AHR (20–22 g.w.)
women (p = 0.003, ANOVA). The lactate N.I. did not
differ between AHR and SYM women who delivered
preterm and their respective counterparts who delivered at
term.
3.6 Acetate
The acetate N.I. was higher in the preterm than the term
group for the SYM (p = 0.003) (about twofold) and AHR
(20–22 g.w.) women (p = 0.048). Acetate N.I. was not
significantly different in other study cohorts in relation to
delivery gestation.
3.7 Alanine
There was a non-significant trend to higher alanine N.I. in
the preterm-delivered SYM women in relation to their term
counterparts (p = 0.056). The alanine N.I. did not differ
significantly between preterm and term-delivered women
in the AHR groups.
3.8 Succinate, glucose and glutamate/glutamine
The SYM women who delivered preterm showed a non-
significant trend to higher succinate N.I. compared to their
term counterparts (p = 0.08). The AHR (20–22 g.w.)
women who delivered at term had a non-significant higher
glutamine/glutamate N.I. compared to their preterm-de-
livered counterparts (p = 0.09).
No differences in glucose N.I. were observed in any
cohorts in relation to delivery outcomes.
No significant differences in the metabolite N.I. were
observed between the AHR (26–28 g.w.) who delivered at
term versus preterm.
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3.9 Vaginal pH
Significantly lower vaginal pH was observed in ALR
women compared to the AHR (20–22 g.w.) women
(p\ 0.001). There was a significant negative correlation
between vaginal fluid lactate N.I. and pH (r = -0.62,
p\ 0.0001) (Fig. 3a, b).
3.10 Predictive performance of metabolites
for preterm birth
Analysis of the area under the ROC curves for the study
metabolites showed that the acetate N.I. was highly
predictive of women presenting with symptoms of PTL
who delivered prematurely (\37 and\32 g.w.), and within
2 weeks of the index assessment (Table 2; Fig. 4). The
other metabolites did not show predictive potential for PTB
for any study cohorts.
3.11 PCR detection of important vaginal organisms
Qualitative PCR assessment of microbial composition of
the vaginal microbome revealed the presence of higher
prevalence of potentially pathogenic anaerobes (i.e.
Gardnerella, Fusobacterium, Bacteroides, Mobiluncus,
Table 1 Clinical characteristics of the study participants
Characteristics Asymptomatic low risk
women, 20–22 g.w.
Asymptomatic high risk
women, 20–22 g.w.
Asymptomatic high risk
women, 26–28 g.w.
Symptomatic women,
24–36 g.w.
Pretermb Term Preterm Term Preterm Term Preterm Term
Age (years) 29 29.6 ± 0.5
(19–39)
82
32.4 ± 1.1
(19–45)
25
30.9 ± 0.8
(19–39)
44
31.4 ± 1.1
(24–39)
17
30.1 ± 0.9
(19–40)
39
29.4 ± 2.4*
(22–48)
11
26.4 ± 0.8
(16–44)
54
BMI (kg m-2) 26.3 25.9 ± 0.6
(14.7–42.2)
82
28.5 ± 1.3
(18.2–46.5)
25
27.0 ± 0.8
(18.2–40.4)
44
27.5 ± 1.3
(18.2–34.1)
17
28.5 ± 0.8
(18.2–40.4)
39
26.6 ? 0.9a
(23.1–30.2)
7
25.4 ± 0.7a
(17.4–41.6)
48
Previous history of
PTB (n)
NA NA 18 35 12 30 NA NA
Cervical length (mm) 37 41.0 ± 0.8**
(29–66)
82
28.4 ± 2.4
(13–53)
21
36.4 ± 1.2*
(18–49)
39
24.2 ± 2.6
(8–40)
17
34.6 ± 1.4*
(15–50)
37
26.8 ± 7.5a
(9–45)
4
32.4 ± 1.7a
(14–54)
25
Fetal fibronectin conc.
(ng/ml)
4 16.3 ± 3.2**
(1–187)
81
100.9 ± 29.5
(2–453)
21
29.4 ± 6.2
(2–157)
37
131.1 ± 35.4*
(3–442)
16
18.6 ± 5.7
(1–159)
35
190.5 ± 185a
(6–375)
2
15.7 ± 3.9a
(2–74)
26
Gestational age at study
(days)
142 141 ± 0.6
(132–159)
82
146 ± 2.0
(115–165)
26
147 ± 1.7
(103–175)
45
189 ± 1.5
(182–205)
17
188 ± 1.0
(173–203)
41
209 ± 6.4
(187–257)
11
213 ± 3.5
(139–254)
54
Gestational age at birth
(days)
238 281 ± 1.0
(258–299)
82
223 ± 6.6
(146–253)
25
274 ± 1.3
(260–290)
45
235 ± 5.1
(187–253)
16
275 ± 1.4
(260–295)
41
224 ± 7.5
(187–257)
11
276 ± 1.2
(260–295)
50
Vagina pH 4.1 3.9 ± 0.04**
(3.6–5)
82
4.3 ± 0.1
(3.6–5.3)
21
4.2 ± 0.1
(3.6–5.6)
38
4.2 ± 0.2
(3.6–6.1)
17
4.1 ± 0.1
(3.6–4.7)
37
4.0 ± 0.2a
(3.6–4.4)
3
4.3 ± 0.1a
(3.6–6.1)
25
Prevalence of PTB, % 1.2 36.6 29.3 16.9
Data are presented as mean ± SE (range) n
Italics indicate groups with significant differences
g.w. gestational weeks, BMI body mass index, PTB preterm birth, NA not applicable
* Differences between term and preterm-delivered women within the group, p\ 0.05
** Differences between term-delivered ALR women and the AHR (20–22 g.w.) women, p B 0.01
a Low study participants population (N) due to absence of consent
b Single member of cohort
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and Mycoplasma species) in the preterm-delivered women
compared to term counterparts especially in the SYM
women (Supplementary Table S2).
4 Discussion
We have studied six potential metabolite markers of PTB
using 1H NMR (Fig. 1), in the two clinical cohorts that
pose prediction challenges in clinical practice: asymp-
tomatic high-risk pregnant women (who are at risk of
recurrence) and women presenting with symptoms of PTL
which are often spurious and may not ultimately lead to
preterm delivery. We describe the variation in normalized
integrals in a subset of CVF metabolites of pregnant
women judged to be at low or high risk of PTB on the basis
of past history across mid/late gestations, as well as those
women who present with symptoms of PTL.
Our pilot observations showed significant predictive
ability for CVF acetate in SYM women who delivered
prematurely before 37, as well as before 32 weeks, and
within 14 days of presentation. Restricting the criteria for
prematurity to birth before 32 weeks or within 14 days of
presentation reduced the PPV and NPV from the ROC
analysis due to the smaller size of the cohorts. Nonetheless,
the lower PPVs and NPVs were still comparable to those of
the current predictive markers for PTB used in clinical
practice i.e. fetal fibronectin, phIGFBP-1 and cervical
length (Heng et al. 2015). The limited number of women in
these smaller cohorts who delivered preterm highlights the
need for larger studies to confirm or refute these findings.
Confirmation of our observations could enable better
stratification of pregnant women and optimization of their
clinical care. The high negative predictive values attained
in our series also suggest that low acetate N.I. may prove a
good ‘‘rule-out’’ test for imminent premature birth,
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Fig. 1 One dimensional 1H
NMR spectrum for metabolites
observed in cervicovaginal fluid
(CVF) samples and sterile swab
(red). ppm parts per million
(Color figure online)
Fig. 2 Data are presented as mean ± SE. Only one preterm delivery
was recorded in the asymptomatic low risk group. ALR asymptomatic
low risk women, AHR asymptomatic high risk women, SYM
symptomatic women, g.w. gestation weeks. *p value\0.05 consid-
ered statistically significant (Color figure online)
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enabling women to be discharged to outpatient care and
thus providing maternal reassurance. Whether CVF acetate
will improve the prognostic performance of currently-em-
ployed assessment modalities such as ultrasound cervical
length (Crane and Hutchens 2008; Mella and Berghella
2009), and fetal fibronectin (Honest et al. 2009), remains to
be determined in adequately-powered prospective studies.
The nature and origin of the CVF metabolites is unclear.
Their profile is thought to result from host mucosal-mi-
crobial metabolism of sugars and proteins within that
milieu. Indeed changes in vaginal bacterial community
composition have been linked to changes in the metabolite
signature (Gajer et al. 2012), and have been implicated in
ascending intrauterine infection (Romero et al. 2001,
2006), leading to spontaneous PTL (Andrew et al. 2000;
Romero et al. 2001). This is a plausible explanation of our
finding of a link between acetate, higher prevalence pro-
portions of mixed anaerobes (i.e. Gardnerella, Fusobac-
terium, Bacteroides, Mobiluncus, Mycoplasma) and PTB.
However, data on vaginal microbial communities of
pregnant women is conflicting, with some studies failing to
demonstrate any difference between women who deliver
preterm and term (Romero et al. 2014).
We have observed elevated CVF lactate N.I. associated
with lower pH in the low-risk asymptomatic cohort con-
sisting of pregnant women with no history of PTB. Inter-
estingly, only one woman in this group delivered preterm
in our series. In contrast, the vaginal fluid lactate N.I. of the
higher risk AHR and SYM cohorts were lower, with cor-
respondingly higher vaginal fluid alkalinity (Table 1;
Fig. 3 a Cervicovaginal fluid pH between the different cohorts.
Box plots show the median line, with the box edges representing the
25 and 75 % quartiles. Whiskers extend to the furthermost value
within 1.5 times the interquartile range from 25 to 75 % quartiles.
b Vaginal fluid pH values versus normalized lactate integral, preterm
and term groups. The correlation was virtually identical for all groups
irrespective of delivery outcome, demonstrating that lactate contribute
the most to pH. Black line represents a linear fit, r = -0.62,
p\ 0.0001. Red line represents a log10 fit. pH range 3.6–6.1. ASYM
asymptomatic women (ALR asymptomatic low risk and AHR
20–22 g.w. women) AHR asymptomatic high risk women, SYM
symptomatic women, g.w. gestational weeks (Color figure online)
Table 2 Predictive performance of acetate normalised integrals for preterm birth in symptomatic pregnant women
Variables \37 weeks
gestation
B32 weeks
gestation
B2 weeks of index
assessment
Area under the ROC curve (AUC) 0.78 0.74 0.84
Standard error, SE 0.09 0.13 0.1
95 % confidence interval 0.61–0.95 0.48–0.99 0.64–1.00
Significance level, p 0.0005 0.04 0.0006
Youden index, J 0.83 0.48 0.69
Sensitivity, % 73 100 100
Specificity, % 83 48 69
Positive predictive value (PPV), % 47 15 27
Negative predictive value (NPV), % 94 100 100
Positive likelihood ratio, LR? 4.4 1.9 3.3
Negative likelihood ratio, LR- 0.2 0.5 0.3
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Fig. 3a), consistent with the long-established observation
that these changes are characteristic of BV, a risk factor for
PTB (Beghini et al. 2014; Donders et al. 2009; Klebanoff
et al. 2005; Lamont and Taylor-Robinson 2010). Support-
ing this view we observed a higher prevalence of anaerobic
organisms in the preterm-delivered symptomatic women
compared to their term counterparts (Table S1). It has been
postulated that large amounts of acetate produced by
vaginal anaerobes may contribute to the pro-inflammatory
environment associated with preterm labour and birth
(Chaudry et al. 2004; Mirmonsef et al. 2012; Romero et al.
2004). Furthermore, increased vaginal acetate is a feature
of infection by the anaerobic pathogenic species seen in
BV (Al-Mushrif et al. 2000; Chaudry et al. 2004; Mir-
monsef et al. 2012), consistent with our findings that SYM
women who delivered preterm and/or within 2 weeks of
presentation had greater than twofold higher acetate, lower
lactate N.I.s as well as higher prevalence of plausibly
subclinical colonization with BV-associated species. This
is also supportive of the unproven thesis that reduced
acidity of CVF, resulting from a change in the microflora
from the normal commensal pattern predominated by
Lactobacillus species to a more diverse community with
increased anaerobic species, may play a role in inflam-
mation-induced PTB. It is plausible that when the bacterial
flora responsible for the much higher acetate N.I. observed
in the preterm SYM attain a functional metabolic threshold
they may well provide a ‘trigger’ for preterm delivery.
However larger prospective studies, as well as studies with
a functional mechanistic design, will be required to explore
this thesis.
A recent study employed liquid and gas chromatography
mass spectrometry (GCMS) techniques to highlight that the
CVF metabolite fingerprint is altered several weeks before
preterm compared to term delivery (Ghartey et al. 2015).
Our findings employing NMR at similar gestational time
points support this finding. Additionally, we have pin-
pointed elevated CVF acetate N.I., not accurately demon-
strable using GCMS techniques owing to the relative
volatility of acetate (Srinivasan et al. 2015), in women
presenting at later gestations with symptoms of PTL who
deliver preterm. Also, we observed a non-significant trend
Fig. 4 Performance of acetate integrals in predicting preterm delivery in symptomatic pregnant women. a\37 g.w. b B32 g.w. c Within
2 weeks of index assessment. AUC area under the ROC curve
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to higher glutamine/glutamate N.I. in the AHR 20–22 g.w.
women who delivered at term compared to their preterm-
delivered counterparts. Glutamate levels identified by
GCMS is negatively correlated with elevated vaginal pH
and L. iners dominated microflora (Srinivasan et al. 2015),
which has been associated with intermediate vaginal flora,
BV and PTB (Elovit et al. 2014; MacKlaim et al. 2013;
Petricevic et al. 2014).
It is of note that several vaginal anaerobes produce
succinate from glycogen. However, although there was a
trend towards increased succinate N.I. in the CVF of
women presenting with symptoms of PTL who delivered
prematurely, this was not statistically significant, indicating
that this mechanism may not be highly active in the bac-
terial communities of our cohorts. Succinate is produced by
anaerobic fermentation of glycogen during infection (Al-
Mushrif et al. 2000; Chaudry et al. 2004; Gajer et al.
2012;), by Prevotella and Mobiluncus (Al-Mushrif et al.
2000; Donders et al. 2002; Graham et al. 2013), species
that we detected in more of the preterm-delivered SYM
women (Supplementary Table S2), contributing to the non-
significant trend observed.
Our data in relation to alanine N.I. is somewhat variable
and unclear. Vaginal microflora produce alanine through
transamination of pyruvate (Chen et al. 1982), and
increased alanine concentrations has been reported in CVF
in non-specific vaginitis and BV states (Chen et al. 1982),
in which the fluid is rich in amino acids and peptides due to
the ascendency of proteolytic organisms such as P. bivia,
G. vaginalis, Mobiluncus (Eschenbach 1989; McGregor
et al. 1986; Paavonen 1983; Thomason et al. 1988;
Schoonmaker et al. 1991). The latter organisms produce
succinate and acetate (Pybus and Onderdonk 1997, Al-
Mushrif et al. 2000), and elevate vaginal pH (Aldunate
et al. 2015).
We did not observe any significant differences in the
metabolite N.I. between the AHR (26–28 g.w.) who
delivered at term versus preterm, and in comparison to
other cohorts. Although the explanation for this observa-
tion is unclear, a proportion of women in this cohort
received clinical interventions (such as cervical cerclage,
and treatment with progesterone or antibiotics) and it may
be speculated that these could have altered metabolite
expression levels and underlines the problems inherent in
clinical studies of PTB. All women studied in all cohorts
had conventional care and ethical constraints precluded any
studies that withheld routine clinical care from any study
participants. To avoid clinical interventions confounding
our results, and in order to bypass this problem, we studied
the SYM group before any clinical intervention had been
commenced. The preterm-delivered women in this group
had altered metabolite profiles compared to their term-de-
livered counterparts and were studied at a mean later
gestation than the AHR and ALR cohorts. The AHR group
were studied at two earlier gestational time points as part of
their routine clinical follow-up protocol at our hospital. It is
plausible that had they been studied again at later gesta-
tions comparable to the SYM group significant differences
in metabolite profiles may have been noted. Future studies
will be required involving larger cohort sizes to elucidate
the influence of such interventions as tocolytic, antibiotic,
progesterone, and steroid therapy on the vaginal metabo-
lome. To bypass ethical limitations such studies will need
to employ a logistic regression prediction model to control
for confounding variables.
Our study identifies promising applications of cervico-
vaginal organic acid assays (particularly acetate) for
prognosticating PTB. Our findings also suggest that
understanding the metabolite signature of pregnant women
may clarify the pathogenesis of inflammation-induced
PTB. However the study has several limitations. We have
so far identified only a limited number of metabolites and
further studies on larger numbers of parturients and
metabolites (e.g. D/L-lactate ratios), under controlled
physiological conditions, will be required to elucidate a
metabolite signature of PTB. The dynamic nature of the
vaginal ecosystem (Gajer et al. 2012; Ravel et al. 2011,
2013; Srinivasan et al. 2010), and individual variations in
CVF volume, may influence study observations. However,
our standardization of sample preparation, inclusion of
‘mock’ sterile swabs and the normalization of the
metabolite integrals to the total spectrum integral have
largely negated these potential variations.
The causes of PTB are multi-factorial and the correla-
tion of the metabolite profile with new or existing prog-
nostic assessments may enhance predictive ability. Going
forward, absolute quantification of metabolites would
facilitate potential clinical translation of metabolite assays
but would present several methodological challenges.
Furthermore, we have studied participants at specific ges-
tational time points and it is plausible that the expression of
metabolites change across the full gestational time spec-
trum in a way that was not observed in this study. A larger
and more diverse cohort with stricter inclusion/exclusion
criteria could confirm and strengthen our findings and
allow stratification of the cohorts in relation to the risk of
PTB.
5 Concluding remarks
We have reported high acetate N.I. and increased detection
of potentially pathogenic anaerobes, in the CVF of preg-
nant women presenting with symptoms of PTL who ulti-
mately deliver before 37 weeks and within 2 weeks of
assessment. Understanding the mechanisms and functional
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implications of these observations, as well as determining
whether quantitative CVF acetate has clinically useful
predictive potential for PTB, requires further investigation
in larger studies.
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